These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

387 related items for PubMed ID: 16479514

  • 1. Comparison of an anti-rabies human monoclonal antibody combination with human polyclonal anti-rabies immune globulin.
    Goudsmit J, Marissen WE, Weldon WC, Niezgoda M, Hanlon CA, Rice AB, Kruif Jd, Dietzschold B, Bakker AB, Rupprecht CE.
    J Infect Dis; 2006 Mar 15; 193(6):796-801. PubMed ID: 16479514
    [Abstract] [Full Text] [Related]

  • 2. [Development of Recombinant Human Monoclonal Antibody Cocktail for Post-exposure Rabies Prophylaxis].
    Sun L, Liu Y, Li C, Li D, Liang M.
    Bing Du Xue Bao; 2016 Jul 15; 32(4):399-403. PubMed ID: 29979531
    [Abstract] [Full Text] [Related]

  • 3. Novel human monoclonal antibody combination effectively neutralizing natural rabies virus variants and individual in vitro escape mutants.
    Bakker AB, Marissen WE, Kramer RA, Rice AB, Weldon WC, Niezgoda M, Hanlon CA, Thijsse S, Backus HH, de Kruif J, Dietzschold B, Rupprecht CE, Goudsmit J.
    J Virol; 2005 Jul 15; 79(14):9062-8. PubMed ID: 15994800
    [Abstract] [Full Text] [Related]

  • 4. Development of a cocktail of recombinant-expressed human rabies virus-neutralizing monoclonal antibodies for postexposure prophylaxis of rabies.
    Prosniak M, Faber M, Hanlon CA, Rupprecht CE, Hooper DC, Dietzschold B.
    J Infect Dis; 2003 Jul 01; 188(1):53-6. PubMed ID: 12825170
    [Abstract] [Full Text] [Related]

  • 5. First administration to humans of a monoclonal antibody cocktail against rabies virus: safety, tolerability, and neutralizing activity.
    Bakker AB, Python C, Kissling CJ, Pandya P, Marissen WE, Brink MF, Lagerwerf F, Worst S, van Corven E, Kostense S, Hartmann K, Weverling GJ, Uytdehaag F, Herzog C, Briggs DJ, Rupprecht CE, Grimaldi R, Goudsmit J.
    Vaccine; 2008 Nov 05; 26(47):5922-7. PubMed ID: 18804136
    [Abstract] [Full Text] [Related]

  • 6. Evaluation of the safety and immunogenicity of a new, heat-treated human rabies immune globulin using a sham, post-exposure prophylaxis of rabies.
    Lang J, Gravenstein S, Briggs D, Miller B, Froeschle J, Dukes C, Le Mener V, Lutsch C.
    Biologicals; 1998 Mar 05; 26(1):7-15. PubMed ID: 9637744
    [Abstract] [Full Text] [Related]

  • 7. Alanine scanning of the rabies virus glycoprotein antigenic site III using recombinant rabies virus: implication for post-exposure treatment.
    Papaneri AB, Wirblich C, Marissen WE, Schnell MJ.
    Vaccine; 2013 Dec 02; 31(49):5897-902. PubMed ID: 24120673
    [Abstract] [Full Text] [Related]

  • 8. Postexposure treatment of rabies infection: can it be done without immunoglobulin?
    Wilde H, Khawplod P, Hemachudha T, Sitprija V.
    Clin Infect Dis; 2002 Feb 15; 34(4):477-80. PubMed ID: 11797174
    [Abstract] [Full Text] [Related]

  • 9. Identification and characterization of a human monoclonal antibody that potently neutralizes a broad panel of rabies virus isolates.
    Sloan SE, Hanlon C, Weldon W, Niezgoda M, Blanton J, Self J, Rowley KJ, Mandell RB, Babcock GJ, Thomas WD, Rupprecht CE, Ambrosino DM.
    Vaccine; 2007 Apr 12; 25(15):2800-10. PubMed ID: 17240489
    [Abstract] [Full Text] [Related]

  • 10.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 11. Use of mouse anti-rabies monoclonal antibodies in postexposure treatment of rabies.
    Schumacher CL, Dietzschold B, Ertl HC, Niu HS, Rupprecht CE, Koprowski H.
    J Clin Invest; 1989 Sep 12; 84(3):971-5. PubMed ID: 2760222
    [Abstract] [Full Text] [Related]

  • 12. Novel rabies virus-neutralizing epitope recognized by human monoclonal antibody: fine mapping and escape mutant analysis.
    Marissen WE, Kramer RA, Rice A, Weldon WC, Niezgoda M, Faber M, Slootstra JW, Meloen RH, Clijsters-van der Horst M, Visser TJ, Jongeneelen M, Thijsse S, Throsby M, de Kruif J, Rupprecht CE, Dietzschold B, Goudsmit J, Bakker AB.
    J Virol; 2005 Apr 12; 79(8):4672-8. PubMed ID: 15795253
    [Abstract] [Full Text] [Related]

  • 13.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 14.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 15.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 16. Rabbit anti-rabies immunoglobulins production and evaluation.
    Liu X, Liu Q, Feng X, Tang Q, Wang Z, Li S, Feng Z, Zhu J, Guan X.
    Trop Biomed; 2011 Apr 12; 28(1):138-48. PubMed ID: 21602780
    [Abstract] [Full Text] [Related]

  • 17.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 18. Negative effects of a disulfide bond mismatch in anti-rabies G protein single-chain antibody variable fragment FV57.
    Duan Y, Gu T, Zhang X, Jiang C, Yuan R, Li Z, Wang D, Chen X, Wu C, Chen Y, Wu Y, Kong W.
    Mol Immunol; 2014 Jun 12; 59(2):136-41. PubMed ID: 24598312
    [Abstract] [Full Text] [Related]

  • 19. Validation of the rapid fluorescent focus inhibition test for rabies virus-neutralizing antibodies in clinical samples.
    Kostense S, Moore S, Companjen A, Bakker AB, Marissen WE, von Eyben R, Weverling GJ, Hanlon C, Goudsmit J.
    Antimicrob Agents Chemother; 2012 Jul 12; 56(7):3524-30. PubMed ID: 22547629
    [Abstract] [Full Text] [Related]

  • 20. Engineering of a recombinant trivalent single-chain variable fragment antibody directed against rabies virus glycoprotein G with improved neutralizing potency.
    Turki I, Hammami A, Kharmachi H, Mousli M.
    Mol Immunol; 2014 Feb 12; 57(2):66-73. PubMed ID: 24091293
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 20.